| Document |
Document Title |
|
WO/2022/266758A1 |
Provided herein are compounds including a linear polyglycerol, a peptide tag, with either a linker-sugar-sialic acid moiety or a sulfate group, a preservation solutions including the compounds, methods for using the compounds or the pres...
|
|
WO/2022/265964A1 |
Described herein are orally-bioavailable nucleoside analogs and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of coronavirus infections, including SARS-CoV-2 in...
|
|
WO/2022/264171A1 |
The present disclosure provides compounds of Formula I and a process of preparing the compounds of Formula I. The present disclosure further provides a compound of Formula II, Formula III, and Formula IV. The present disclosure provides ...
|
|
WO/2022/260545A1 |
The subject of the invention is a new methotrexate-glucose conjugate derivative, its synthesis, and its use in the treatment and prevention of neoplasms, preferably in the treatment and prevention of neoplasms selected from: skin cancer,...
|
|
WO/2022/260546A1 |
The invention relates to a glucose-methotrexate conjugate for use in the prevention or treatment of autoimmune diseases, in particular rheumatoid arthritis or psoriasis.
|
|
WO/2022/256920A1 |
Provided herein are β-1,3-linked biopolymers (acholetin polysaccharides). Furthermore, provided herein are enzymatic methods and systems for producing β-1,3-linked oligosaccharides and polysaccharides using β-1,3-N-acetylglucosaminide...
|
|
WO/2022/254867A1 |
Provided is a novel active ingredient derived from carob and a use thereof. The present invention is a compound represented by formula (I) or a salt thereof, or a solvate of the compound or the salt.
|
|
WO/2022/254083A1 |
The present invention relates to a method for producing cationic saccharides byreacting saccharide with a compound having a conjugated electron withdrawing group via oxa-Michael addition reaction for producing a derivatized saccharidefol...
|
|
WO/2022/255417A1 |
Provided are: a method for efficiently producing a catechin conjugate by means of a semi-synthetic method; and a production intermediate of said catechin conjugate. The present invention provides a method for producing an allylated cat...
|
|
WO/2022/251730A1 |
Provided are 13-membered ribosome targeting compounds that can be used to treat genetic diseases, including genetic diseases that are associated with a premature termination codon mutation or other nonsense mutation. The compounds can in...
|
|
WO/2022/246195A1 |
Provided herein are functional moieties, functionalized compounds and macromolecules, their preparation, and uses thereof.
|
|
WO/2022/238696A1 |
The present disclosure describes a novel class of masking agents that can be activated under ionising radiation. The masking agents (which in some cases may be referred to as protecting groups) can be conjugated, linked or bonded to a pa...
|
|
WO/2022/234966A1 |
The present invention relates to a method for separating and purifying a sophorolipid having improved physical properties, such as specific odor, color, and viscosity, from acidic-type and lactone-type sophorolipid precipitation solution...
|
|
WO/2022/232900A1 |
The present application provides a liposomal composition that multivalently displays a specific glycan ligand, or combination of specific glycan ligands, to specifically target CD33 on microglial cells. Multivalent engagement of CD33 wit...
|
|
WO/2022/233623A1 |
Suggested are new microbial glycolipids of formula (I), wherein X stands for nitrogen or oxygen; R1 represents hydrogen, -CO-Alkyl, -CO-Aryl, -CO-N-Alkyl, -CO-N-Aryl, SO2-Alkyl, SO2-Aryl, -CO(CH2)nCOOH with n=1 to 4, or an amino acid; R2...
|
|
WO/2022/234287A1 |
The present invention relates to imidazo[1,2-b]pyridazine compounds and pharmaceutically acceptable salts thereof. The invention also relates to the processes for the preparation of the compounds, compositions containing the compounds, a...
|
|
WO/2022/229377A1 |
The present invention relates to new amphiphilic perfluorinated compounds and their use as a detergent for extracting membrane-proteins or synthesizing membrane-proteins in acellular system. It also relates to a method for extracting a m...
|
|
WO/2022/222249A1 |
Involved is a method for obtaining 1-N-ethyl gentamicin C1a by using hydrolysis in a pipeline reactor. The method comprises the following steps: 1) pumping an etimicin synthesis solution and a NaOH solution into a temporary storage tank ...
|
|
WO/2022/220625A1 |
The present invention relates to protein degrader conjugates and a use thereof. Particularly, the present invention relates to antigen-specific binding moiety-protein degrader conjugates, and a use of the antigen-specific binding moiety-...
|
|
WO/2022/220521A1 |
The present invention relates to an amphipathic compound, a preparation method therefor, and a surfactant composition comprising same and, specifically, to a compound selected from the group consisting of steviol monoglycoside-acid, stev...
|
|
WO/2022/219094A1 |
The present invention relates to a process for producing isomalt compositions enriched in 1-O-α-D-glucopyranosyl-D-mannitol (hereinafter 1,1-GPM) and/or in 6-O-α-D-glucopyranosyl-D-sorbitol (hereinafter 1,6-GPS) from isomalt-containing...
|
|
WO/2022/221393A1 |
The present application relates to triterpene glycoside saponin-derived adjuvants, TLR4 agonists and antagonists, TLR9 agonists and antagonists, and combinations thereof, as well as pharmaceutical compositions comprising the foregoing an...
|
|
WO/2022/216922A1 |
The present invention relates to novel steviol glycosides rebaudioside R6-5, rebaudioside R6-6, and rebaudioside R7-5 and the production of these novel steviol glycosides, such as through enzymatic bioconversion.
|
|
WO/2022/210011A1 |
[Problem] To provide a novel sophorolipid derivative that has high water-solubility and is surface active. [Solution] A plurality of sophorolipid derivatives having novel structures were isolated and purified from a cultured product of a...
|
|
WO/2022/207699A1 |
The present invention pertains to enzyme-triggered self-reacting arm compounds, chemical intermediates used for preparing such compounds and uses thereof, specifically in prodrug design and conjugation technologies. The present invention...
|
|
WO/2022/207086A1 |
The present invention is directed to a process for isolating and/or purifying glycolipids from a glycolipid-containing composition wherein said process comprises the steps of: providing a process-unit with an adsorbent, wherein said adso...
|
|
WO/2022/208544A1 |
This invention relates to the inhibitory activity of the combination of a natural chemical entity Artocarpin with standard drug gentamycin against different multi drug-resistant and susceptible strains of S. aureus. (Formula I) The syner...
|
|
WO/2022/200273A2 |
A method for selective cyclization or de-cyclization of a mix of sophorolipids in the lactonic or acidic forms, wherein the lactonic form is produced by reacting a mixture of sophorolipids with a strong methylating agent to provide an en...
|
|
WO/2022/204449A1 |
The present invention provides a biocompatible low molecular weight (LMW) hydrogel having a high storage modulus that comprises water and thioglycolipid. The invention also provides a carrier material and an article of manufacture compri...
|
|
WO/2022/183254A1 |
The invention relates inter alia to methods of producing sulfated oligosaccharide derivatives and intermediates thereof. The sulfated oligosaccharide derivatives may be represented by the following formula (I) wherein: X and Y are any D-...
|
|
WO/2022/187141A1 |
Compounds for activating invariant natural killer T cells (iNKT) cells are provided. Compounds according to certain embodiments activate iNKT cells and induce an increase in the production of one or more cytokines, such as IFNγ, IL-2, I...
|
|
WO/2022/187361A1 |
This disclosure is directed to N-substituted valiolamine compounds, their use as glycosidase inhibitors, and in methods of treating diseases or conditions in which glycosidase inhibition provides benefit.
|
|
WO/2022/183562A1 |
A glucocerebroside compound, a pharmaceutical composition thereof, and the use of the glucocerebroside compound and the pharmaceutical composition thereof in the preparation of drugs for preventing or treating immune-related diseases.
|
|
WO/2022/181695A1 |
The purpose of the present disclosure is to provide: a complex of a cell and a material; a method for producing a complex of a cell and a material; and a novel compound that can be used to obtain said complex. In a complex according to...
|
|
WO/2022/178057A1 |
A process is provided for the synthesis of an intermediate which is useful in the synthesis of E-selectin inhibitors. Also provided are useful intermediates obtained from the process.
|
|
WO/2022/168846A1 |
A barrier function improver which contains methylhesperidin as an active ingredient, and a barrier function improver composition which contains said barrier function improver and a pharmaceutically acceptable carrier.
|
|
WO/2022/162161A1 |
The present invention provides novel conjugated oligonucleotide compounds, which are suitable for therapeutic use. Additionally, the present invention provides methods of making these compounds, as well as methods of using such compounds...
|
|
WO/2022/162992A1 |
The present invention addresses the problem of providing a new pharmaceutical composition that can treat a T cell-independent reaction or an early phase reaction (a symptom in an early phase) of an allergic disease. Examples of the pre...
|
|
WO/2022/162154A1 |
The present invention provides novel conjugated oligonucleotide compounds, which are suitable for therapeutic use. Additionally, the present invention provides methods of making these compounds, as well as methods of using such compounds...
|
|
WO/2022/162153A1 |
The present invention relates to novel conjugated oligonucleotide compounds, which are suitable for therapeutic use. Additionally, the present invention provides methods of making these compounds, as well as methods of using such compoun...
|
|
WO/2022/162157A1 |
The present invention relates to novel conjugated oligonucleotide compounds, which are suitable for therapeutic use. Additionally, the present invention provides methods of making these compounds, as well as methods of using such compoun...
|
|
WO/2022/157233A1 |
The present invention relates to compounds of the following formula (I): as well as their preparation process; their use in cosmetic or dermatological applications, in particular for the treatment and/or prevention of skin aging, skin pr...
|
|
WO/2022/156424A1 |
An amphiphilic molecular self-assembly nanodrug for tumor treatment, a preparation method therefor and a use thereof. Specifically disclosed is an amphiphilic compound, which is a conjugate of a hydrazine group-modified organic photother...
|
|
WO/2022/150924A1 |
Carbohydrate of Formula (A) where R1 is H and n an integer from 1 to 5, is synthesized by reacting, under heating, compound (A0) with HO-(CH2)n-CH=CH2 in the presence of an acid capable of liberating a proton, and cooling the reaction mi...
|
|
WO/2022/155518A1 |
The present disclosure provides, benzimidazole derivatives and antibody-drug conjugates thereof which act as STING agonists and are useful in treating various diseases such as cancer.
|
|
WO/2022/149074A1 |
Provided is an adjuvant composition comprising a glycoarchaeol and at least one immunostimulantselected from a Toll-like receptor (TLR) agonist and a saponin. The glycoarchaeol and/orimmunostimulant may be present as a pharmaceutically a...
|
|
WO/2022/146137A1 |
The present invention relates to a compound, represented by formula (I): (I) wherein a) R, R1, R2 and R4 are independently of one another a hydrogen 0 atom or a C1-C6 linear or branched alkyl, or a C1-C6 linear or branched alkenyl, or a ...
|
|
WO/2022/135319A1 |
The present invention relates to a method for the automatic preparation of a fondaparinux sodium pentasaccharide intermediate. The method is based on an automatic preparation device. According to the method, automatic preparation of thre...
|
|
WO/2022/133480A1 |
The present invention provides AHR agonists, composites thereof, and methods of using the same.
|
|
WO/2022/130238A1 |
A new process for the synthesis of amide derivatives of 8-hydroxypenicillanic acid is described, more specifically starting from amide derivatives of the 6-aminopenicillanic nucleus protected as tert-butylcarbamate.
|
